Plain-English translation of NCT07036731 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a simple urine DNA test can help doctors decide which bladder cancer patients really need a second surgery and which ones don't. Many patients with early-stage bladder cancer are given a second surgery as standard care, but this test may help avoid unnecessary procedures in some patients. Researchers want to see if this approach is as safe and effective as the standard treatment.
Bladder cancer patients often undergo a second surgery to make sure all cancer is removed, but this second procedure carries risks and isn't always necessary. This trial exists to see whether a urine test that detects cancer DNA can reliably predict which patients can safely skip the second surgery, potentially sparing them from an unnecessary procedure while keeping them just as safe.
You likely qualify if…
You likely don't qualify if…
After your first bladder cancer surgery, you will provide a urine sample that will be sent for DNA testing. Depending on your test results, you will either proceed with the standard second surgery, or be randomly assigned to either skip the second surgery or have it as usual. After that, you will be followed by your doctor for two years with regular check-ups to monitor for any cancer recurrence.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China